Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trimodulin for severe community-acquired pneumonia in ventilated adults (phase III)
2022-501352-28-00Phase 3Authorised
- Sponsor
- Biotest AG
- Start
- Jun 2023
- Modality
- Antibody-Based Therapeutics
- Countries
- 21
01
Overview
Phase 3, randomised, double-blind trial in community-acquired pneumonia (CAP) comparing Trimodulin arm with Placebo arm (2 arms). Primary endpoint: 28-day all-cause mortality rate. Planned start Jun 2023; status: authorised.
02
Drugs
Pentaglobin
03
Conditions
community-acquired pneumonia (CAP)
Beyond the preview
Go deeper on 2022-501352-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501352-28-00.